Leo Pharma agrees to pay $437K to settle lawsuit over skin cancer risk from Picato
Toronto-based Leo Pharma has agreed to pay $437,678 to settle a class action lawsuit alleging that its actinic keratosis treatment, Picato, increased patients’ risk of developing squamous cell carcinoma, a type...To view the full article, register now.
Already a subscriber? Click here to view full article